Bought ginkgo bioworks
WebOct 7, 2024 · For Gingko Bioworks to reach that level, shares would need to trade at $3.57. Here’s the math. Current market cap – $22 billion First half of 2024 revenues – $87.73 million Annualized revenues ($87.73 million * 2) = $175.46 million Current simple valuation ratio = 22 / .17546 = 125 WebJun 28, 2024 · Ginkgo Bioworks Holdings has a market capitalization of US$5.0b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the...
Bought ginkgo bioworks
Did you know?
WebFeb 24, 2024 · Ginkgo Bioworks is looking for ways to streamline its cellular engineering processes. So far, using AI hasn't been enough to make its business profitable. Improvements to its margins could lead...
WebDec 21, 2024 · Thanks to its ground-breaking synthetic biology projects, the company is reportedly valued at more than $1 billion after raising over $429 million in total funding from its investors, who include... WebMar 13, 2024 · In This Article. Ginkgo Bioworks Holdings Inc. has $74 million in the recently failed Silicon Valley Bank, all of it inherited from an acquisition it spent $300 …
WebApr 8, 2024 · Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Rating) insider Reshma P. Shetty sold 37,650 shares of the stock in a transaction on Wednesday, April 5th. The stock was sold at an average price of $1.22, for a total value of $45,933.00. Following the transaction, the insider now owns 13,767,604 shares of the company's stock, valued at … WebSep 17, 2024 · At the time of the business combination announcement, analysts estimated Ginkgo Bioworks at a $15 billion pre-money equity valuation and expected the deal to …
WebApr 10, 2024 · Polianta Ltd lifted its holdings in Ginkgo Bioworks by 108.2% during the 1st quarter. Polianta Ltd now owns 732,300 shares of the company’s stock valued at $973,000 after buying an additional 380,600 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Ginkgo Bioworks in the fourth quarter worth approximately ...
WebApr 7, 2024 · Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $477.7 million with a -440.6% net profit margin. Year-over-year quarterly sales growth most recently was -33.8%. Analysts expect adjusted earnings to reach $-0.345 per share for the current fiscal year. Ginkgo Bioworks Holdings Inc does not currently pay a dividend. bob\u0027s driving school omahaWebMar 6, 2024 · As we mentioned earlier, Ginkgo Bioworks stock is finally trading at a simple valuation ratio ( market cap/annualized revenue) where we could consider an investment. In the span of about 18 months, the company has lost about 80% of its original valuation at the time of the SPAC merger. bob\u0027s dry cleaners lima ohioWebApr 6, 2024 · For instance, while Beam Therapeutics and Ginkgo Bioworks lost over 21% this year, Verve Therapeutics stock declined over 29% in the period. Some of these companies witnessed important ... clive dennis chiropractorWebSep 17, 2024 · Key Points. Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece ... bob\u0027s drive in sunnyside wa menuWebOct 7, 2024 · The flagship Ark Innovation ETF bought 6.7 million shares in the synthetic biology company, while the Genomic Revolution ETF picked up 1.5 million. Together, the … cliveden locationWebApr 7, 2024 · Ginkgo Bioworks (NYSE: DNA) is in the red today, despite a recent transaction with $182 billion investment firm Baillie Gifford. Based on an amended 13G … bob\u0027s drugs hesperia miWebDec 21, 2024 · In March 2015, Ginkgo raised $9 million from investors as part of the company's first significant fundraising round before picking up another $45 million (from a … cliveden nursing and rehab